Prophylactic Vaccine Targeting TLR3 on Dendritic Cells Ameliorates Eosinophilic Pneumonia in a Mouse SARS-CoV Infection Model.
Immunohorizons
; 6(4): 275-282, 2022 04 27.
Article
in English
| MEDLINE | ID: covidwho-1818325
ABSTRACT
Putative subcomponent vaccines of severe acute respiratory syndrome coronavirus spike protein and ARNAX (TLR3-specific adjuvant for priming dendritic cells) were examined and compared with spike protein + Alum in a mouse BALB/c model. Survival, body weight, virus-neutralizing Ab titer in the blood, and viral titer in the lung were evaluated for prognosis markers. The infiltration degrees of eosinophils in the lung were histopathologically monitored at 10 d postinfection. The results were (1) adjuvant was essential in vaccines to achieve a complete recovery from infection, (2) ARNAX displayed optimal body weight recovery compared with Alum, (3) ARNAX was optimal for the amelioration of eosinophilic pneumonia, and (4) the eosinophil infiltration score was not associated with the neutralizing Ab titer in the blood or viral titer in the lung. Although the pathological link between the TLR3 vaccine and lung eosinophil infiltration remains unclear, severe acute respiratory syndrome-mediated eosinophilic pneumonia can be blocked by the prior induction of dendritic cell priming by ARNAX.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pulmonary Eosinophilia
/
Viral Vaccines
/
Severe acute respiratory syndrome-related coronavirus
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Vaccines
Limits:
Animals
Language:
English
Journal:
Immunohorizons
Year:
2022
Document Type:
Article
Affiliation country:
Immunohorizons.2200020
Similar
MEDLINE
...
LILACS
LIS